Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
FIBROGEN INC (FGEN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Quarterly results
Docs: "FibroGen Reports Second Quarter 2023 Financial Results • Topline data from three late-stage pamrevlumab trials expected through 1H 2024, including the Pancreatic Cancer Action Network Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer • Robust roxadustat volume growth of over 40% in China • Entered into exclusive license for FOR46, a first-in-class CD46-targeting antibody-drug conjugate for the treatment of metastatic castration-resistant prostate cancer • Implemented cost reduction plan extending cash runway into 2026 • Thane Wettig appointed Interim CEO"
08/04/2023 144 Form 144 - Report of proposed sale of securities:
07/25/2023 8-K Quarterly results
07/19/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
07/19/2023 8-K Quarterly results
07/11/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 144 Form 144 - Report of proposed sale of securities:
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/08/2023 144 Form 144 - Report of proposed sale of securities:
06/08/2023 144 Form 144 - Report of proposed sale of securities:
06/08/2023 144 Form 144 - Report of proposed sale of securities:
06/07/2023 144 Form 144 - Report of proposed sale of securities:
06/07/2023 144 Form 144 - Report of proposed sale of securities:
06/07/2023 144 Form 144 - Report of proposed sale of securities:
06/07/2023 144 Form 144 - Report of proposed sale of securities:
06/07/2023 144 Form 144 - Report of proposed sale of securities:
06/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy – Study did not meet the primary endpoint – Pamrevlumab was generally safe and well tolerated – Topline results from LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with DMD expected 3Q 2023"
06/02/2023 144 Form 144 - Report of proposed sale of securities:
05/31/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/18/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia • Met primary endpoint of noninferiority of roxadustat to erythropoietin alfa • Plan to file supplemental New Drug Application in China"
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "FibroGen Reports First Quarter 2023 Financial Results • Topline Data From Four Phase 3 Trials Expected Through 3Q 2023 • Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value • Entered Into Exclusive License for FOR46 with Fortis Therapeutics"
05/01/2023 8-K Quarterly results
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/27/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/27/2023 10-K Annual Report for the period ended December 31, 2022
02/27/2023 8-K Quarterly results
Docs: "FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results • Topline Data from Five Pivotal Phase 3 Trials in 2023 • Total Company Revenue $140.7 Million in 2022 • Continued Strong Roxadustat Volume Growth in China"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy